Welcome

PanGenex (PGXC) Welcomes Ronald P. Caputo, MD, FACC, FSCAI, to Its Board of Directors

May 06, 2008 09:25 AM Eastern Daylight Time

TAMPA, Fla.--(EON:Enhanced Online News)--PanGenex Corporation (Pink Sheets:PGXC) announces that Dr. Ronald P. Caputo, Director of Cardiology Research at St. Joseph’s Hospital in New York has accepted an invitation to join the Company’s Board of Directors.

“The addition of Dr. Caputo to the PanGenex team is a testament to the product, the research and the organization that has been put together over the last several years”

“The addition of Dr. Caputo to the PanGenex team is a testament to the product, the research and the organization that has been put together over the last several years,” states Jeff Roman, President and CEO, PanGenex Corporation. “To have someone of Dr. Caputo’s caliber interested in actively participating in our business strategy, marketing programs, product formulations and research directives is an important milestone for our company.”

Dr. Caputo brings over 20 years of cardiovascular experience to PanGenex. Dr. Caputo received his undergraduate degree in Biology from Georgetown University and his MD from Georgetown University Medical School in 1988. Postdoctoral internships have included training at the University of Massachusetts Medical Center as well Harvard Medical School and the Beth Israel Hospital in Boston. Dr. Caputo has been an Instructor of Medicine at Harvard Medical School and the University of Massachusetts as well as an Editorial Consultant for the American Journal of Cardiology. Dr. Caputo is licensed in Massachusetts and New York and is certified by the American Board of Internal Medicine in Cardiology and has been published on numerous occasions in such periodicals as the New England Journal of Medicine. Dr. Caputo has been with St. Joseph’s Hospital since 1996.

Dr. Caputo’s interests have gone beyond the clinical setting as he has successfully established and participated in several private companies dedicated to assisting physicians in new product development, engineering, design, patent, legal support, prototype development, pre-clinical and clinical testing, marketing and sales and has mainly focused in the fields of interventional cardiology, peripheral vascular intervention and cardiothoracic surgery. In 1999, Dr. Caputo was the Chairman, Head of Scientific Development and founding partner of AngioLink Corporation which was later acquired by Medtronic Inc. (NYSE). Dr. Caputo continues to be a member of the Medical Advisory Board for Boston Scientific and is recognized as the nation’s foremost entrepreneurial interventional cardiologist by his peers.

Learn More about Dr. Ronald Caputo at: http://www.pangenex.com/management-team.html

About PanGenex Corporation:

PanGenex pursues business opportunities in the nutraceutical and cardiovascular health industries. The Company has developed and markets novel, patented or patent pending, condition specific nutraceuticals, topical over-the-counter (OTC) drugs and personal care products. Healthy Solutions from Science and Nature.™ Visit them on the Web at www.PanGenex.com and www.Calgenex.com.

Disclaimer:

Cautionary Statement about Forward-Looking Statements

This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things: (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. Statements regarding product have not been evaluated by the Food and Drug Administration. The products discussed are not intended to diagnose, treat, cure or prevent any disease.